Provided by Tiger Fintech (Singapore) Pte. Ltd.

LivaNova PLC

39.13
-0.4900-1.24%
Pre-market: 39.10-0.0300-0.08%06:05 EDT
Volume:320.23K
Turnover:12.55M
Market Cap:2.13B
PE:33.73
High:39.63
Open:39.48
Low:39.03
Close:39.62
Loading ...

RECOVER Clinical Study Shows Meaningful Benefits of LivaNova’s VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression

Business Wire
·
18 Dec 2024

LivaNova PLC's (NASDAQ:LIVN) Has Had A Decent Run On The Stock market: Are Fundamentals In The Driver's Seat?

Simply Wall St.
·
30 Nov 2024

LivaNova PLC's (NASDAQ:LIVN) Stock Has Shown A Decent Performance: Have Financials A Role To Play?

Simply Wall St.
·
29 Nov 2024

Wall Street Analysts Predict a 37.2% Upside in LivaNova (LIVN): Here's What You Should Know

Zacks
·
28 Nov 2024

Teladoc Enhances Virtual Sitter With AI for Improved Care Delivery

Zacks
·
27 Nov 2024

LivaNova Price Target Maintained With a $75.00/Share by Needham

Dow Jones
·
25 Nov 2024

BUZZ-Inspire Medical rises after BofA upgrades to 'buy' from 'neutral'

Reuters
·
20 Nov 2024

LivaNova's OSPREY Sleep Apnea Trail on aura6000 Meets Primary Endpoint

Zacks
·
18 Nov 2024

LivaNova to Present at the Stifel, Wolfe, and Piper Sandler Healthcare Conferences

Business Wire
·
14 Nov 2024

Barclays Releases a Hold Rating on LivaNova (LIVN)

TIPRANKS
·
13 Nov 2024

LivaNova Price Target Maintained With a $75.00/Share by Needham

Dow Jones
·
13 Nov 2024

Shareholders Will Be Pleased With The Quality of LivaNova's (NASDAQ:LIVN) Earnings

Simply Wall St.
·
12 Nov 2024

LivaNova Announces Osprey Clinical Study Meets Primary Safety and Efficacy Endpoints

THOMSON REUTERS
·
12 Nov 2024

LivaNova Plc - No Serious Adverse Device-Related or Procedure-Related Events Reported

THOMSON REUTERS
·
12 Nov 2024

LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints

Business Wire
·
12 Nov 2024

LivaNova (LIVN) Upgraded to Strong Buy: What Does It Mean for the Stock?

Zacks
·
08 Nov 2024